Because DKK1 has been demonstrated to be a pathologically essential and strong prognostic factor in several studies, including ours, DKK1 could be a potential candidate for a future preclinical study of anti‐DKK1 therapy in HCC, as described for myeloma (Fulciniti et al., 2009) and osteosarcoma (Goldstein et al., 2016). Here, DKK1 is linked to plasma cell myeloma.